Tag: report

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approximately USD 56.37 Billion in 2024 and is expected to reach USD 66.13 Billion in 2025 and is expected to reach around USD 252.93 Billion by 2034, at a CAGR of 17.32% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Illumina Inc., Precision Biologics, Danaher Corporation (Cepheid Inc.), GE HealthCare, Celera Diagnostics LLC, Decode Genetics Inc., Exact Sciences Corporation, IBM Corporation, Exagen Inc., Biogen, QIAGEN, Genentech Inc., 23andMe Inc., Asuragen Inc and others.

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.

– Total Revenues increased 13.8% for the quarter over the prior year period to $60.3 million –
– Total Written Premium increased 14.4% for the quarter over the prior year period to $450.3 million –
– Organic Revenue Growth Rate* of 10.6% for the quarter –
– Net income of $9.0 million for the quarter –
– Adjusted EBITDA* increased 40.7% for the quarter over the prior year period to $15.1 million –

BOSTON, MA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today announced financial results for the full fiscal year 2025 ended April 30, 2025.

CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its financial and operating results for the second quarter of 2025. The Company’s interim financial statements for the three and six months ended June 30, 2025 and related Management’s Discussion and Analysis (“MD&A”) are available on our website at www.ppr.ca and filed on SEDAR+ at www.sedarplus.ca.